BIO USA 2026
- Korean Drug Developers Turn to Partnering at Bio USA 2026
A broad slate of Korean pharma and biotech firms used Bio USA 2026 to chase partnering deals, from organoid platforms to stem-cell and CDMO work.
- Korean Biotech at BIO USA 2026: Licensing Deals Over Product Launches
Korean drugmakers used BIO USA 2026 to court partners rather than launch products, with Curacle's 1.6 trillion won deal setting the benchmark.
- Korean Biotech at BIO 2026: Kangstem Courts a Partner as Data Nears
Korean drug developers pushed partnering deals at BIO USA 2026, with Kangstem Biotech awaiting late-July Phase 2 data and G2G Bio fresh off its KOSDAQ debut.
- Korean Biotech Takes Home-Built Strengths to BIO USA 2026
At BIO USA 2026, Korean biotech leaders from MediSapiens, G2G Bio and Lotte Biologics pitched global partners on capabilities built at home.
- Korea's Biopharma Makes Its Case at BIO USA 2026
Korean drugmakers from SK Biopharm to DXVX used BIO USA 2026 to court partners across CDMO, clinical analytics and licensing pipelines.
- Korean Biotech's Four-Day Push at BIO USA 2026
Korean pharma and biotech firms used a packed four-day BIO USA 2026 schedule to court partners, from Kanaph Therapeutics to SK Biopharm and DXVX.
